Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration
Early AMD prevention through repurposed therapeutics, guided by AI-driven design and systems biology, may enable personalized care via multimodal risk stratification incorporating genetic, metabolomic, and microbiome data. Rigorous, stratified clinical trials integrating bioinformatics and precision medicine are essential to validate the most effective candidates.
Authors
- Nikita Mokhashi (ORCID: https://orcid.org/0000-0001-9510-3747)
- Dimitra Skondra (ORCID: https://orcid.org/0000-0003-3862-6159)
- Beryl Zhou
Institutions
- University of Chicago (US)
- Hinge Health (US)
Publication Details
- Journal
- Expert Opinion on Drug Discovery
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/17460441.2026.2635492
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00